Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 50 articles:
HTML format
Text format



Single Articles


    September 2017
  1. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Text format     Abstract available


    August 2017
  2. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


    April 2017
  3. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  4. VAN DER REE MH, Jansen L, Kruize Z, van Nuenen AC, et al
    Plasma microRNA levels are associated with HBeAg status and treatment response in chronic hepatitis B patients.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. CHI H, Hansen BE, Guo S, Zhang NP, et al
    Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    J Infect Dis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. CHEN GJ, Lin KY, Hung CC, Chang SC, et al
    Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  7. WANG L, Wen J, Gao F, Hao H, et al
    Hepatitis E virus-associated neurological injury in China.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  8. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  9. HAN Y, Gu L, Liu J, Li X, et al
    Association of mutations in TLR2 signaling genes with fulminant form of hepatitis B related acute liver failure.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. ZHOU X, Huang F, Xu L, Lin Z, et al
    Hepatitis E virus infects neurons and brains.
    J Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


    January 2017
  11. CAO J, Chi H, Yu T, Li Z, et al
    Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    J Infect Dis. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  12. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A Virus Endemic Circulation in Israel Despite Universal Toddler Vaccination Since 1999 and Low Clinical Incidence in All Age Groups.
    J Infect Dis. 2016 Dec 24. doi: 10.1093.
    PubMed     Text format    


  13. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CHEN MH, Chen MH, Liu CY, Tsai CY, et al
    Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment.
    J Infect Dis. 2016 Dec 23. pii: jiw606. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  16. SCHIRDEWAHN T, Grabowski J, Sekyere SO, Bremer B, et al
    The third signal cytokine IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  17. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  18. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  19. WANG L, Wiener J, Bulterys M, Wei X, et al
    Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  20. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  21. HONER ZU SIEDERDISSEN C, Rinker F, Maasoumy B, Wiegand SB, et al
    Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  22. MAYORGA O, Buhler S, Jaeger VK, Bally S, et al
    Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  23. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  24. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  25. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  26. ZEREMSKI M, Dimova RB, Pillardy J, de Jong YP, et al
    Fibrosis Progression in Patients with Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  27. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  28. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Text format     Abstract available


    June 2016
  29. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  30. BEHRENDT P, Bremer B, Todt D, Brown RJ, et al
    Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  31. SHILAIH M, Marzel A, Scherrer AU, Braun DL, et al
    Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  32. SIMONS BC, Spradling PR, Bruden DJ, Zanis C, et al
    A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B cellular immunity despite loss of antibody against hepatitis B surface antigen.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  33. HONDA M, Shirasaki T, Terashima T, Kawaguchi K, et al
    Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    J Infect Dis. 2016;213:1096-106.
    PubMed     Text format     Abstract available


    March 2016
  34. MOQUEET N, Cooper C, Gill J, Hull M, et al
    Responder Interferon Lambda genotypes are associated with higher risk of liver fibrosis in HIV-Hepatitis C Virus Co-infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  35. ARAGRI M, Alteri C, Battisti A, Di Carlo D, et al
    Multiple HBV Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  36. EVANS TI, Li H, Schafer JL, Klatt NR, et al
    SIV-induced Translocation of Bacterial Products in the Liver Mobilizes Myeloid Dendritic and Natural Killer Cells Associated With Liver Damage.
    J Infect Dis. 2016;213:361-9.
    PubMed     Text format     Abstract available


    January 2016
  37. VAN DAMME P
    Long-term Protection After Hepatitis B Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  38. BRUCE MG, Bruden D, Hurlburt D, Zanis C, et al
    Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  39. SAKIANI S, Koh C, Heller T
    Reply to Tennant and Post.
    J Infect Dis. 2016;213:325-6.
    PubMed     Text format    


  40. PIROTH L, Launay O, Michel ML, Bourredjem A, et al
    Vaccination against hepatitis B virus in HIV-1 infected patients with isolated anti-HBc: the ANRS HB EP03 CISOVAC prospective study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  41. MASTRO TD, Morrison CS, Hamilton CD
    Determining Hepatitis C Virus Incidence in Populations: an Important Tool for Epidemic Control.
    J Infect Dis. 2016.
    PubMed     Text format    


  42. PATEL EU, Cox AL, Mehta SH, Boon D, et al
    Hepatitis C IgG antibody avidity as a biomarker to estimate population-level incidence.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  43. MATTHEWS PC, Carlson JM, Beloukas A, Malik A, et al
    HLA-A is a Predictor of Hepatitis B e-Antigen Status in HIV-positive African Adults.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  44. SWANSON S, Ma Y, Scherzer R, Huhn G, et al
    Association of HIV, HCV and Liver Fibrosis Severity with the Enhanced Liver Fibrosis Score.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  45. SVAROVSKAIA ES, Gane E, Dvory-Sobol H, Martin R, et al
    L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  46. LIANG KH, Hsu CW, Chang ML, Chen YC, et al
    Peginterferon is superior to nucleos(t)ide analogs for prevention of hepatocellular carcinoma in chronic hepatitis B.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  47. OLMSTEAD AD
    Digging Deeper into Hepatitis C Virus Outbreaks.
    J Infect Dis. 2015.
    PubMed     Text format    


  48. CAMPO DS, Xia GL, Dimitrova Z, Lin Y, et al
    Accurate genetic detection of hepatitis C virus transmissions in outbreak settings.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  49. LY KN, Klevens RM, Jiles RB
    Reply to Jones.
    J Infect Dis. 2015.
    PubMed     Text format    


    July 2015
  50. HERMANS LE, Svicher V, Pas SD, Salpini R, et al
    Combined Analysis of the Prevalence of drug Resistant HBV in antiviral therapy Experienced patients in Europe (CAPRE).
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: